Compounds that inhibit the interaction between HSP90 and proteins having an M-5 loop, such as EGFR, are disclosed, as are their use in treating EGFR-related diseases, including cancers and solid tumors.Composés inhibant linteraction entre HSP90 et des protéines ayant une boucle M-5, telles que EGFR, ainsi que leur utilisation dans le traitement de maladies associées aux EGFR, y compris des cancers et des tumeurs solides.